TG Therapeutics refinances with $750M term loan due 2031, repays existing debt

Filed March 20, 2026 · Period ending March 18, 2026 · ~1 min read

Key Changes

• high

  Company closed $750M term loan facility on March 18, 2026, using proceeds to fully repay prior term loans. Also established uncommitted $250M additional borrowing capacity for future needs.

  Item 1.01 verify on EDGAR →
• high

  New loan matures March 2031 with interest at SOFR+4.75% (or base rate+3.75%), with 25 basis point rate reduction available if company hits leverage ratio target.

  Item 1.01 verify on EDGAR →
• medium

  Quarterly principal payments of $37.5M begin in Q1 2030, but can be deferred to maturity if company maintains low leverage ratio, providing financial flexibility.

  Item 1.01 verify on EDGAR →